•
Nov 23, 2024
Nov 22, 2024
Nov 18, 2024
Nov 12, 2024
Nov 21, 2024
Nov 20, 2024
Nov 8, 2024
Nov 7, 2024
Nov 6, 2024
VERU INC. [VERU] has reported fiscal Q2 loss of $38.80 million.
On a per-share basis, the WI based company said its diluted earnings are $0.48.
The Pharmaceutical Preparations firm posted revenue of $6.60 million in this period.
Also Read: Veru Reports Fiscal 2023 Second Quarter Financial ResultsVeru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin ...Blue Water Announces Acquisition of ENTADFI®, an FDA-Approved Benign Prostatic Hyperplasia AssetVeru Sells ENTADFI® Business for $20 Million Plus up to an Additional $80 Million from Sales ...Veru Enters Into Supply Agreement with Afaxys to Expand Access to FC2 Female Condom® in U.S. ...